Clinical Updatesasthma progressionbiologics
From Mild-to-Moderate to Severe Asthma: Risk Factors and Patient Profiles from the NORDSTAR Cohort and Advances in Severe Asthma Management
By MedXY|Sep 17, 2026
This review summarizes the progression risk from mild-to-moderate to severe asthma based on the NORDSTAR cohort and integrates emerging evidence on biologic therapies that improve severe asthma outcomes across diverse patient profiles.